Status:
COMPLETED
Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients
Lead Sponsor:
Mahidol University
Conditions:
Sepsis
Septic Shock
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Sepsis and septic shock patients are considered to have a high risk of complications and death. Appropriate antimicrobial therapy plays an important role in determining outcomes in septic patients. Ho...
Eligibility Criteria
Inclusion
- Adults (18 years and older) with sepsis and/or septic shock according to SEPSIS-3 criteria and receive meropenem within 1 hour after diagnosis
- Informed consent signed by patient or their legally authorized representative
Exclusion
- Subjects with infective endocarditis
- Subjects with central nervous system infection
- Subjects who requires surgical condition within 72 hours after randomization
- Subjects on extracorporeal membrane oxygenation (ECMO) within 3 days after randomization
- Subjects with active seizure
- History of receiving meropenem within 1 week prior to randomization
- Pregnancy women and lactation
- Known allergy to meropenem
- Not complete a 72-hour course of empirical meropenem treatment
Key Trial Info
Start Date :
November 27 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2018
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT03344627
Start Date
November 27 2017
End Date
December 31 2018
Last Update
March 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine Ramathibodi Hospital
Ratchathewi, Bangkok, Thailand, 10400